血管紧张素原 来源于人血浆

Hypertensinogen, Renin substrate

np001156-25μg

25μg

BioReagent

≥95%(SDS-PAGE)

血管紧张素原（Angiotensinogen, AGT）是一种糖蛋白，在健康人群血浆中的浓度为 2.8-7.1 毫克 / 100 毫升。AGT 主要由肝脏产生，同时也在大脑、大动脉、肾脏和脂肪组织中合成。在血浆中，它以单体形式（分子量 55-65 千道尔顿）和高分子量形式（分子量 200-550 千道尔顿）存在。 对于血压正常的非妊娠人群，高分子量形式的 AGT 占循环系统中总 AGT 的 3%。在妊娠前半段，总 AGT 水平会增加 4 倍，而高分子量形式的 AGT 会增加 20 倍。在羊水的总 AGT 中，高达 80% 为高分子量形式。 血管紧张素原是肾素 - 血管紧张素系统（renin-angiotensin system, RAS）的关键组成部分，该系统是调节血压、体液及电解质稳态的强效调控系统。AGT 作为人肾素的作用底物，同时也是血管紧张素 1、2、3、4、1-9、1-7、1-5 及 1-4 的前体分子。此外，AGT 属于丝氨酸蛋白酶抑制剂（SERPIN）家族，但目前尚未发现其具有蛋白酶抑制活性。血浆中的 AGT 水平会受血浆皮质类固醇、雌激素、甲状腺激素及血管紧张素 2 水平的影响而升高。 消光系数：0.92 所用血浆经 FDA 要求的检测显示，乙型肝炎表面抗原（HBsAg）、抗丙型肝炎病毒（抗 - HCV）、抗乙型肝炎核心抗体（抗 - HBc）均为阴性，且抗人类免疫缺陷病毒 1 型和 2 型（抗 - HIV 1 & 2）也为阴性。 Angiotensinogen (AGT) is a glycoprotein found in plasma at a concentration of 2.8-7.1 mg per 100mL in healthy individuals. AGT is produced primarily by the liver but also is synthesized in the brain, large arteries, kidneys and adipose tissue. In plasma it exists as a monomeric form (55-65 kDa) as well as a high molecular mass form (200-550 kDa). In non-pregnant individuals with normal blood pressure, the high molecular mass form accounts for 3% of total circulating AGT. In the first half of pregnancy the total AGT increases by 4-fold and the high molecular mass form increases by 20-fold. Up to 80% of the total AGT in amniotic fluid is the high molecular mass form. Angiotensinogen is an essential component of the renin-angiotensin system, a potent regulator of blood pressure, body fluid and electrolyte homeostasis. It functions as the substrate for human renin and is the precursor molecule for Angiotensins 1,2,3,4, 1-9, 1-7, 1-5 and 1-4. AGT is also a member of the SERPIN family but it is not known to possess protease-inhibitory activity. Levels in plasma are increased by plasma corticosteroid, estrogen, thyroid hormone and angiotensin-2 levels. Extinction Coefficient: 0.92 Prepared from plasma shown to be non reactive for HBsAg, anti-HCV, anti-HBc, and negative for anti-HIV 1 & 2 by FDA approved tests.

Essential component of the renin-angiotensin system (RAS), a potent regulator of blood pressure, body fluid and electrolyte homeostasis. Angiotensin-2: Acts directly on vascular smooth muscle as a potent vasoconstrictor, affects cardiac contractility and heart rate through its action on the sympathetic nervous system, and alters renal sodium and water absorption through its ability to stimulate the zona glomerulosa cells of the adrenal cortex to synthesize and secrete aldosterone. Acts by binding to angiotensin receptors AGTR1 and AGTR2. Also binds the DEAR/FBXW7-AS1 receptor (By similarity). Angiotensin-3: Stimulates aldosterone release. Angiotensin 1-7: Is a ligand for the G-protein coupled receptor MAS1 (By similarity). Has vasodilator and antidiuretic effects. Has an antithrombotic effect that involves MAS1-mediated release of nitric oxide from platelets (By similarity). Post-translational modification:Beta-decarboxylation of Asp-25 in angiotensin-2, by mononuclear leukocytes produces alanine. The resulting peptide form, angiotensin-A, has the same affinity for the AT1 receptor as angiotensin-2, but a higher affinity for the AT2 receptor (PubMed:17138938).1 PublicationIn response to low blood pressure, the enzyme renin/REN cleaves angiotensinogen to produce angiotensin-1. Angiotensin-1 is a substrate of ACE (angiotensin converting enzyme) that removes a dipeptide to yield the physiologically active peptide angiotensin-2. Angiotensin-1 and angiotensin-2 can be further processed to generate angiotensin-3, angiotensin-4. Angiotensin 1-9 is cleaved from angiotensin-1 by ACE2 and can be further processed by ACE to produce angiotensin 1-7, angiotensin 1-5 and angiotensin 1-4. Angiotensin 1-7 has also been proposed to be cleaved from angiotensin-2 by ACE2 or from angiotensin-1 by MME (neprilysin). The disulfide bond is labile. Angiotensinogen is present in the circulation in a near 40:60 ratio with the oxidized disulfide-bonded form, which preferentially interacts with receptor-bound renin.

天然

55-65 kDa

NONH for all modes of transport

人(Human)